Trials / Completed
CompletedNCT02334748
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 5 Years – 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306 (NCT02296424) or CACZ885N2301 (NCT02059291) until a decision regarding reimbursement in France is effective for canakinumab (Ilaris®) in these indications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | canakinumab | canakinumab |
Timeline
- Start date
- 2014-11-03
- Primary completion
- 2018-08-31
- Completion
- 2018-08-31
- First posted
- 2015-01-08
- Last updated
- 2020-05-19
- Results posted
- 2020-05-19
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02334748. Inclusion in this directory is not an endorsement.